Kaskela Law is investigating Summit Therapeutics (NASDAQ: SMMT) (“Summit”) on behalf of the company’s current shareholders.
The investigation seeks to determine whether Summit and/or the company’s officers and directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.
Summit shareholder are encouraged to contact Kaskela Law (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional information about this investigation and their legal rights and options at (484) 229 – 0750, by email at [email protected], or by completing the form on this page.